Skip to content
DataLookout
Menu

ZUPREME-5NCT07843472

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Trial sites expanded: 3 → 11 locations
  2. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage Change in Body Weight from Baseline
Timeframe: From Baseline to Week 64

Secondary (42)

Proportion of Participants Achieving ≥ 5% Body Weight Loss from Baseline
Proportion of Participants Achieving ≥ 10% Body Weight Loss from Baseline
Proportion of Participants Achieving ≥ 15% Body Weight Loss from Baseline
Change from Baseline in Waist Circumference (cm)
Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Show 37 moreShow less
Change from Baseline in Triglycerides
Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQoL-Lite-CT) Physical Functioning Composite Score
Change from Baseline in IWQoL-Lite-CT Physical Functioning Composite Score in Participants with Poor Physical Functioning at Baseline (as defined by Patient Global Impression of Severity/Status [PGI-S])
Change from Baseline in Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score in Participants with Poor Physical Functioning at Baseline (as defined by PGI-S)
Change from Baseline in Mean Daily Food Craving Score
Change from Baseline in Mean Daily Peak Hunger Score
Change from Baseline in Body Mass Index (BMI) (kg/m²)
Change from Baseline in Body Weight (kg)
Change from Baseline in Waist-to-Hip Ratio
Change from Baseline in Waist-to-Height Ratio
Change from Baseline in Fasting Insulin
Change from Baseline in Fasting Glucose
Change from Baseline in Hemoglobin A1c (HbA1c)
Percentage of Participants with Type 2 Diabetes at Screening Achieving HbA1c of < 5.7%
Percentage of Participants with Type 2 Diabetes at Screening Achieving HbA1c of < 6.5%
Percentage of Participants with Type 2 Diabetes at Screening Achieving HbA1c of < 7%
Percentage of Participants With Baseline Prediabetes Achieving HbA1c of < 5.7%
Change from Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol
Change from Baseline in Non-HDL Cholesterol
Change from Baseline in Total Cholesterol
Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol
Change from Baseline in Free Fatty Acids
Change from Baseline in Systolic Blood Pressure
Change from Baseline in Diastolic Blood Pressure
Change from Baseline in Health-Related Quality of Life (HRQoL) as assessed by SF-36v2 Acute Form Domain Scores and Component Summary Scores
Change from Baseline in HRQoL as assessed by IWQoL-Lite-CT Domain Scores and Total Score
Proportion of Participants with ≥ 14.6-Point Increase from Baseline in IWQoL-Lite-CT Physical Function Score
Proportion of Participants with ≥ 3.7-Point Increase from Baseline in SF36v2 Physical Functioning Score
Proportion of Participants with Baseline Poor Physical Functioning Achieving ≥ 14.6-Point Increase in IWQoL-Lite-CT Physical Functioning Score
Proportion of Participants with Baseline Poor Physical Functioning Achieving a ≥ 3.7-Point Increase in SF36v2 Physical Functioning Score
Change from Baseline in Mean Daily Average Hunger Score
Change from Baseline in Mean Daily Average Satiety Score
Change from Baseline in Mean Daily Average Appetite Score
Incidence and Severity of Adverse Events, with Severity Determined According to Mild/Moderate/Severe Criteria
Percentage of Participants with Baseline Anti-Drug Antibodies (ADAs) and Treatment-Emergent ADAs Against Petrelintide

Arms and interventions

PetrelintideExperimental
PlaceboPlacebo comparator

Combination products: Petrelintide, Placebo

Sites

11 sites in 3 countries

United States 6, United Kingdom 4, Taiwan 1